OIS@AAO 2013
Moderating an informative conversation surrounding FDA procedures and communication, Emmett Cunningham, Summit Chairman, draws detailed responses from Wiley Chambers and Malvina Eydelman of the FDA.…
Read MoreJeffrey Hoffman, Managing Director and Head of West Coast Healthcare Investment Banking for JPMorgan, gladly addresses the audience at the 5th Annual Ophthalmology Innovation Summit…
Read MoreWilliam J. Link PhD, Managing Director for Versant Ventures, announces the winners of the 2013 OIS Innovator Award. Describing the caliber and achievement that merits…
Read MoreDetailing the grueling process and levels of determination necessary to go public, David Guyer, CEO for Ophthotech, begins this panel discussion with some of the…
Read MoreOphthalmic Innovation 2013 – “A View from the NEI” Paul Sieving, Director for the National Eye Institute, leads the attendees at the 5th Annual Ophthalmology…
Read MoreAmarpreet Sawhney, President & CEO for Ocular Therapeutix, shares the company’s vision of becoming the leading developer of sustained ophthalmic therapies. Striving to improve patient…
Read MoreTed Danse, President & CEO for Neurotech, begins by touching upon their ETC technology platform, labeling it as “transformational” in its ability to deliver biologics…
Read MoreVicken Karageozian, Co-Founder & CTO for Allegro Ophthalmics, shares his company’s story and highlights the progress of their lead molecule, ALG1001, a lead program for…
Read MoreJack Elands, CEO for Amakem, talks about his company’s focus on a localized drug action platform, and details the company’s feature glaucoma product to lower…
Read MoreWilliam S. (Sandy) White, President & CEO for Icon BioSciences, discusses the company’s increasing portfolio of products that target most major therapeutic areas of ophthalmology.…
Read More[creativ_media type=”vimeo” url=”https://vimeo.com/82003104″] Guillaume Pfefer, President & CEO, shares Kala Pharmaceutical’s breakthrough technology Nucleolus Penetrating Particle with the audience of the 5th Annual Ophthalmology Innovation…
Read MoreBernhard Gunther, CEO for Novaliq GmbH, introduces their approach to improving topical ocular track delivery. Detailing the challenges involved, Bernhard expands on their unique opportunity…
Read More- « Previous
- 1
- 2
- 3
- Next »
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")